WM
MCID: WLD007
MIFTS: 61

Waldenstroem's Macroglobulinemia (WM)

Categories: Blood diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Waldenstroem's Macroglobulinemia

MalaCards integrated aliases for Waldenstroem's Macroglobulinemia:

Name: Waldenstroem's Macroglobulinemia 11 14
Waldenstrom Macroglobulinemia 11 19 42 58 53 43 16 71
Macroglobulinemia of Waldenstrom 19 42
Waldenström Macroglobulinemia 42 75
Lymphoplasmacytic Lymphoma with Igm Gammopathy 11
Malignant Lymphoma - Lymphoplasmacytic 71
Waldenstrom's Macroglobulinaemia 19
Waldenstrom's Macroglobulinemia 42
Waldenström's Macroglobulinemia 75
Lymphoplasmacytic Lymphoma 19
Waldenstrom's Syndrome 19
Wm 42

Characteristics:


Inheritance:

Waldenstrom Macroglobulinemia: Multigenic/multifactorial 58

Prevelance:

Waldenstrom Macroglobulinemia: 1-9/1000000 (Europe, United States, United Kingdom, Spain) 1-9/100000 (France, Europe) 58

Age Of Onset:

Waldenstrom Macroglobulinemia: Elderly 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare haematological diseases


Summaries for Waldenstroem's Macroglobulinemia

MedlinePlus Genetics: 42 Waldenström macroglobulinemia is a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow.  These abnormal cells have characteristics of both white blood cells (lymphocytes) called B cells and more mature cells derived from B cells known as plasma cells. These abnormal cells with both lymphocyte and plasma characteristics are known as lymphoplasmacytic cells. Due to these cells, Waldenström macroglobulinemia is classified as a lymphoplasmacytic lymphoma. In Waldenström macroglobulinemia, these abnormal cells produce excess amounts of IgM, the largest of a type of protein known as an immunoglobulin; the overproduction of this large protein contributes to the condition's name (macroglobulinemia). Waldenström macroglobulinemia usually begins in a person's sixties and is a slow-growing (indolent) cancer. Some affected individuals have elevated levels of IgM and lymphoplasmacytic cells but no symptoms of the condition; in these cases, the disease is usually found incidentally by a blood test taken for another reason. These individuals are diagnosed with smoldering (or asymptomatic) Waldenström macroglobulinemia. It can be many years before a person with the condition develops noticable signs and symptoms.The most common signs and symptoms to first appear in people with Waldenström macroglobulinemia are weakness and extreme tiredness (fatigue) caused by a shortage of red blood cells (anemia). Affected individuals can also experience general symptoms such as fever, night sweats, and weight loss. Some people with Waldenström macroglobulinemia develop a loss of sensation and weakness in the limbs (peripheral neuropathy). Doctors are unsure why this feature occurs, although they speculate that the IgM protein attaches to the protective covering of nerve cells (myelin) and breaks it down. The damaged nerves cannot carry signals normally, leading to neuropathy.Other features of Waldenström macroglobulinemia are due to the accumulation of lymphoplasmacytic cells in different tissues. For example, accumulation of these cells can lead to an enlarged liver (hepatomegaly), spleen (splenomegaly), or lymph nodes (lymphadenopathy). In the bone marrow, the lymphoplasmacytic cells interfere with normal blood cell development, causing a shortage of healthy blood cells (pancytopenia). Several other signs and symptoms of Waldenström macroglobulinemia are related to the excess amounts of IgM. Increased IgM can thicken blood and impair circulation, causing a condition known as hyperviscosity syndrome. Features related to hyperviscosity syndrome include bleeding in the nose or mouth, blurring or loss of vision, headache, dizziness, and confusion. In some affected individuals, IgM and other immunoglobulins react to cold temperatures to form gel-like clumps that block blood flow in areas exposed to the cold, such as the hands and feet. These clumped proteins are referred to as cryoglobulins, and their clumping causes a condition known as cryoglobulinemia. Cryoglobulinemia can lead to pain in the hands and feet or episodes of Raynaud phenomenon, in which the fingers and toes turn white or blue in response to cold temperatures. The IgM protein, along with another protein called amyloid, can build up in organs and interfere with their normal function. This buildup causes a condition called amyloidosis. Organs that are typically affected by amyloidosis include the heart, kidneys, liver or spleen. Affected individuals can experience weakness, fatigue, shortness of breath, irregular heartbeat, or joint pain.

MalaCards based summary: Waldenstroem's Macroglobulinemia, also known as waldenstrom macroglobulinemia, is related to lymphoplasmacytic lymphoma and burkitt lymphoma. An important gene associated with Waldenstroem's Macroglobulinemia is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Toll-like receptor signaling pathway and B Cell Receptor Signaling Pathway. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, b cells and spleen, and related phenotypes are leukemia and lymphoma

GARD: 19 Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Affected individuals have a high level of an antibody called immunoglobulin M (IgM) in their blood, which can cause thickening of the blood (hyperviscosity). Although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. Other symptoms may include peripheral neuropathy, fever, Raynaud's phenomenon, and mental status changes. Hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. The cause of the condition is not known but environmental, genetic, and viral factors have been suggested. There have been some reports of familial cases suggesting a genetic predisposition.

Orphanet: 58 Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoproliferative disorder characterized by the accumulation of monoclonal cells in the bone marrow and peripheral lymphoid tissues, and associated with the production of serum immunoglobulin M (IgM) monoclonal protein.

Disease Ontology: 11 A lymphoplasmacytic lymphoma characterized by the accumulation of monoclonal cells in the bone marrow and peripheral lymphoid tissues, and associated with the production of serum immunoglobulin M (IgM) monoclonal protein.

Wikipedia: 75 Waldenström macroglobulinemia (/ˈvɑːldənstrɛm ˌmækroʊˌɡlɒbjələˈniːmiə/) is a type of cancer affecting... more...

Related Diseases for Waldenstroem's Macroglobulinemia

Diseases related to Waldenstroem's Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 581)
# Related Disease Score Top Affiliating Genes
1 lymphoplasmacytic lymphoma 32.5 PAX5 MYD88 MIR9-1 MAG IRF4 CCND1
2 burkitt lymphoma 31.4 PAX5 MS4A1 MIR155 IRF4 CD40LG CD40
3 macroglobulinemia 31.3 PAX5 MYD88 HAS1 CD40LG CD40 BTK
4 lymphoma 31.0 PTPRC PAX5 MYD88 MS4A1 IRF4 CD40LG
5 marginal zone b-cell lymphoma 30.9 PAX5 MYD88 IRF4 CCND1 BTK BIRC3
6 diffuse large b-cell lymphoma 30.8 PAX5 MYD88 MIR9-1 MIR155 IRF4 BTK
7 splenic marginal zone lymphoma 30.7 PAX5 MYD88 CCND1 BIRC3
8 b-cell lymphoma 30.6 ZAP70 PTPRC PAX5 MYD88 MS4A1 IRF4
9 agammaglobulinemia 30.5 IRF4 CD40LG CD40 BTK
10 plasma cell neoplasm 30.5 PTPRC PAX5 MYD88 MIR155 CCND1
11 lymphoma, hodgkin, classic 30.5 ZAP70 PTPRC PAX5 MS4A1 MIR9-1 MIR155
12 leukemia, chronic lymphocytic 2 30.5 ZAP70 MS4A1
13 monoclonal gammopathy of uncertain significance 30.5 PTPRC MYD88 MAG IRF4 CCND1
14 chronic lymphocytic leukemia/small lymphocytic lymphoma 30.5 ZAP70 PAX5 CCND1 BTK
15 bone lymphoma 30.5 PTPRC PAX5 IRF4
16 bone marrow cancer 30.5 PTPRC MIR9-1 MIR155 CCND1
17 plasmacytoma 30.4 PTPRC PAX5 IRF4 CCND1
18 angioimmunoblastic t-cell lymphoma 30.4 PAX5 MIR155 IRF4
19 agammaglobulinemia, x-linked 30.4 CD40LG CD40 BTK
20 anemia, autoimmune hemolytic 30.4 ZAP70 CD40LG BTK
21 hematologic cancer 30.4 ZAP70 PAX5 MIR9-1 MIR155 IRF4
22 prolymphocytic leukemia 30.4 ZAP70 MS4A1 CCND1
23 richter's syndrome 30.3 ZAP70 PAX5 BTK BIRC3
24 extramedullary plasmacytoma 30.3 PTPRC PAX5 IRF4 CCND1
25 toxoplasmosis 30.3 MYD88 MIR155 CD40LG
26 gastrointestinal lymphoma 30.2 CCND1 BIRC3
27 plasma cell leukemia 30.2 IRF4 CD40 CCND1
28 follicular lymphoma 30.2 PAX5 MS4A1 MIR155 IRF4 CD40LG CD40
29 peripheral t-cell lymphoma 30.2 ZAP70 PTPRC PAX5 MS4A1 MIR155
30 central nervous system lymphoma 30.1 PAX5 MYD88 MIR9-1 IRF4 BTK
31 lymphoma, mucosa-associated lymphoid type 30.1 ZAP70 PAX5 MYD88 MIR155 IRF4 CD40
32 leukemia, chronic myeloid 30.0 PTPRC MIR9-1 MIR155 IRF4 CCND1 BIRC3
33 primary central nervous system lymphoma 30.0 PAX5 MYD88
34 severe combined immunodeficiency 30.0 ZAP70 PTPRC CD40LG CD40
35 combined immunodeficiency 30.0 ZAP70 PTPRC IRF4 CD40LG CD40 BTK
36 mature b-cell neoplasm 30.0 PTPRC PAX5 MIR9-1 MIR155 IRF4 CD40
37 lymphoma, non-hodgkin, familial 29.9 PTPRC PAX5 MYD88 MS4A1 MIR9-1 MIR155
38 peripheral nervous system disease 29.9 PTPRC MIR9-1 MIR542 MAG CCND1
39 skin disease 29.8 ZAP70 PTPRC MYD88 MIR9-1 MIR155 CD40LG
40 connective tissue disease 29.8 PTPRC MYD88 MIR9-1 MIR542 MIR494 MIR155
41 leukemia, chronic lymphocytic 29.7 ZAP70 PTPRC PAX5 MYD88 MS4A1 MIR9-1
42 immune deficiency disease 29.7 ZAP70 PTPRC MS4A1 MIR9-1 MIR155 CD40LG
43 myeloma, multiple 29.5 PTPRC PAX5 MYD88 MIR9-1 MIR155 MAG
44 leukemia, acute lymphoblastic 29.5 ZAP70 PTPRC PAX5 MIR9-1 MIR155 IRF4
45 leukemia, acute myeloid 29.5 PTPRC PAX5 MIR9-1 MIR542 MIR184 MIR155
46 mantle cell lymphoma 29.3 ZAP70 PTPRC PAX5 MYD88 MIR9-1 MIR155
47 lymphoplasmacytic lymphoma without igm production 11.3
48 macroglobulinemia, waldenstrom 1 11.3
49 polyclonal hyperviscosity syndrome 11.3
50 amyloidosis 10.5

Comorbidity relations with Waldenstroem's Macroglobulinemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Neutropenia

Graphical network of the top 20 diseases related to Waldenstroem's Macroglobulinemia:



Diseases related to Waldenstroem's Macroglobulinemia

Symptoms & Phenotypes for Waldenstroem's Macroglobulinemia

Human phenotypes related to Waldenstroem's Macroglobulinemia:

58 30 (show all 45)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 leukemia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001909
2 lymphoma 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002665
3 monoclonal immunoglobulin m proteinemia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0005508
4 respiratory insufficiency 58 30 Frequent (33%) Frequent (79-30%)
HP:0002093
5 pallor 58 30 Frequent (33%) Frequent (79-30%)
HP:0000980
6 vertigo 58 30 Frequent (33%) Frequent (79-30%)
HP:0002321
7 gingival bleeding 58 30 Frequent (33%) Frequent (79-30%)
HP:0000225
8 abnormality of neutrophils 58 30 Frequent (33%) Frequent (79-30%)
HP:0001874
9 hypercoagulability 58 30 Frequent (33%) Frequent (79-30%)
HP:0100724
10 normocytic anemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001897
11 ataxia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001251
12 hearing impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000365
13 splenomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001744
14 hepatomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002240
15 malabsorption 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002024
16 reduced consciousness/confusion 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004372
17 fatigue 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012378
18 renal insufficiency 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000083
19 fever 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001945
20 cranial nerve paralysis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0006824
21 congestive heart failure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001635
22 abnormal retinal vascular morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0008046
23 anorexia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002039
24 proptosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000520
25 purpura 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000979
26 gastrointestinal hemorrhage 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002239
27 stroke 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001297
28 periorbital edema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100539
29 peripheral neuropathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0009830
30 epistaxis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000421
31 migraine 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002076
32 urticaria 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001025
33 vasculitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002633
34 memory impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002354
35 cutis marmorata 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000965
36 retinal hemorrhage 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000573
37 recurrent infections 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002719
38 pleural effusion 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002202
39 diarrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002014
40 lymphadenopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002716
41 pulmonary infiltrates 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002113
42 elevated erythrocyte sedimentation rate 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003565
43 pedal edema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010741
44 multifocal epileptiform discharges 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010841
45 cryoglobulinemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100778

MGI Mouse Phenotypes related to Waldenstroem's Macroglobulinemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.8 BIRC3 BTK CCND1 CD40 CD40LG HAS1
2 hematopoietic system MP:0005397 9.47 BIRC3 BTK CCND1 CD40 CD40LG HAS1

Drugs & Therapeutics for Waldenstroem's Macroglobulinemia

Drugs for Waldenstroem's Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 249)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
3
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
4
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
5
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
6
Etoposide Approved Phase 4 33419-42-0 36462
7
Cytarabine Approved, Investigational Phase 4 147-94-4 6253
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9 Anti-Bacterial Agents Phase 4
10 Anti-Infective Agents Phase 4
11 Immunosuppressive Agents Phase 4
12 Angiogenesis Inhibitors Phase 4
13
Etoposide phosphate Phase 4 16760419
14
Chlorambucil Approved Phase 3 305-03-3 2708
15
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
16
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 60-18-4, 556-02-5 1153 6057
17
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
18 HIV Protease Inhibitors Phase 3
19
protease inhibitors Phase 3
20 Antineoplastic Agents, Hormonal Phase 3
21 Hormones Phase 3
22 Hormone Antagonists Phase 3
23 Antiemetics Phase 3
24 glucocorticoids Phase 3
25 Anti-Inflammatory Agents Phase 3
26 BB 1101 Phase 3
27 Gastrointestinal Agents Phase 3
28 Alkylating Agents Phase 3
29 Antineoplastic Agents, Alkylating Phase 3
30 Cc-486 Phase 2, Phase 3
31
Belimumab Approved Phase 2 356547-88-1
32
Ichthammol Approved Phase 1, Phase 2 8029-68-3
33
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
34
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704
35
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560
36
Adenosine Approved, Investigational Phase 2 58-61-7 60961
37
Pentostatin Approved, Investigational Phase 2 53910-25-1 439693
38
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
39
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
40
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
41
Atorvastatin Approved Phase 2 134523-00-5 60823
42
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
43
Iron Approved Phase 2 7439-89-6 29936
44
Deferasirox Approved, Investigational Phase 2 201530-41-8 214348 5493381
45
Mecobalamin Approved, Investigational Phase 1, Phase 2 13422-55-4
46
Hydroxocobalamin Approved Phase 1, Phase 2 13422-51-0 15589840 44475014
47
Iodine Approved, Investigational Phase 2 7553-56-2 807
48
Sildenafil Approved, Investigational Phase 2 139755-83-2, 171599-83-0 5212 135398744
49
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
50
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690

Interventional clinical trials:

(show top 50) (show all 329)
# Name Status NCT ID Phase Drugs
1 Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844361 Phase 4
2 The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China Unknown status NCT02844322 Phase 4 Bortezomib;Rituximab
3 The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844309 Phase 4 Thalidomide
4 A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia Active, not recruiting NCT04042376 Phase 4 Ibrutinib
5 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Unknown status NCT02991638 Phase 3 Ibrutinib
6 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
7 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
8 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
9 A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Completed NCT03053440 Phase 3 BGB-3111;Ibrutinib
10 A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
11 Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
12 iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia Completed NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
13 Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib Alone in Waldenström's Macroglobulinemia (CZAR-1) Recruiting NCT04263480 Phase 3 Carfilzomib + Ibrutinib;Ibrutinib
14 Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia Recruiting NCT04061512 Phase 2, Phase 3 Dexamethasone, cyclophosphamide, rituximab;Rituximab, ibrutinib
15 Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Active, not recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
16 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Enrolling by invitation NCT01804686 Phase 3 Ibrutinib
17 A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements Suspended NCT04799275 Phase 2, Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Oral Azacitidine;Prednisone;Vincristine Sulfate
18 A Phase 2 Study to Evaluate the Efficacy of Bortezomib in Patients With De-novo Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma Unknown status NCT03335098 Phase 2 Bortezomib
19 A Multicenter, Single-arm, Phase II Study to Evaluate a Safety and Efficacy of Obinutuzumab Induction Followed by 2 Years of Maintenance in Patients With Relapsed/Refractory Waldenström Macroglobulinemia. Unknown status NCT03679455 Phase 2 Obinutuzumab 25 MG/ML
20 Velcade/Dexamethasone/Cyclophosphamide(PCD) Versus Rituximab /Dexamethasone/Cyclophosphamide(RCD) for the Treatment of Patients With Waldenstrom's Macroglobulinemia Unknown status NCT02971982 Phase 1, Phase 2 rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide
21 Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Unknown status NCT02981745 Phase 1, Phase 2 CT-1530
22 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
23 A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
24 A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients With Relapsed Waldenstrom Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom Macroglobulinemia (Phase II) Completed NCT01381692 Phase 1, Phase 2 Bortezomib;Dexamethasone;Temsirolimus
25 A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid
26 Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia Completed NCT02677324 Phase 2 ABT199
27 A Phase IIA Trial Testing the Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00777738 Phase 2 BORTEZOMIB
28 A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial Completed NCT00789776 Phase 1, Phase 2 Cyclophosphamide;Fludarabine Phosphate;Mycophenolate Mofetil;Tacrolimus
29 A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE), and Dexamethasone (R-CYBOR-D) in Relapsed Low Grade and Mantle Cell Lymphoma Completed NCT00711828 Phase 2 Bortezomib;Cyclophosphamide;Dexamethasone
30 A Phase I/II Trial of CpG 7909, Rituximab Immunotherapy, and Y-90 Zevalin Radioimmunotherapy for Patients With Previously Treated CD20+ Non-Hodgkin Lymphoma Completed NCT00438880 Phase 1, Phase 2 Agatolimod Sodium
31 Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas Completed NCT01076543 Phase 1, Phase 2 Lenalidomide;Temsirolimus
32 Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
33 A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma Completed NCT03364231 Phase 2 Umbralisib
34 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
35 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
36 UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia Completed NCT00083707 Phase 2 Thalidomide
37 A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Completed NCT01109069 Phase 2 PCI-32765
38 Rituximab and Dexamethasone in CD20 Positive Low Grade and Follicular Non-Hodgkin's Lymphoma Completed NCT00244855 Phase 2 dexamethasone
39 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
40 Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial Completed NCT00096161 Phase 2 Cyclosporine;Mycophenolate Mofetil;Pentostatin
41 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
42 A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial Completed NCT01251575 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
43 A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed NCT01261247 Phase 2 panobinostat
44 Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation Completed NCT01527045 Phase 2 Atorvastatin Calcium;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
45 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
46 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
47 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Completed NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
48 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
49 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
50 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2

Search NIH Clinical Center for Waldenstroem's Macroglobulinemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorambucil
Cyclophosphamide
Ibrutinib
Thalidomide

Cochrane evidence based reviews: waldenstrom macroglobulinemia

Genetic Tests for Waldenstroem's Macroglobulinemia

Anatomical Context for Waldenstroem's Macroglobulinemia

Organs/tissues related to Waldenstroem's Macroglobulinemia:

MalaCards : Bone Marrow, B Cells, Spleen, Bone, Liver, Heart, T Cells

Publications for Waldenstroem's Macroglobulinemia

Articles related to Waldenstroem's Macroglobulinemia:

(show top 50) (show all 2474)
# Title Authors PMID Year
1
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. 62 46
19074725 2009
2
Bortezomib as a treatment option in patients with Waldenström macroglobulinemia. 53 62
20371443 2010
3
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. 53 62
19047284 2009
4
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. 53 62
18815290 2008
5
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. 53 62
18537966 2008
6
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. 53 62
18452095 2008
7
Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia. 53 62
18326744 2008
8
Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. 53 62
16960805 2006
9
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. 53 62
16983704 2006
10
Translocation t(9;14)(p13;q32) in cases of splenic marginal zone lymphoma. 53 62
16956840 2006
11
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique. 53 62
16280661 2005
12
Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. 53 62
16231851 2005
13
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. 53 62
16034042 2005
14
Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia. 53 62
15794859 2005
15
How we treat Waldenström's macroglobulinemia. 53 62
15642678 2005
16
Treatment options in Waldenstrom's macroglobulinemia. 53 62
15636690 2004
17
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. 53 62
15493038 2004
18
Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. 53 62
14764523 2004
19
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. 53 62
15133473 2004
20
Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). 53 62
15116325 2004
21
Waldenström macroglobulinaemia. 53 62
14602248 2003
22
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. 53 62
12881316 2003
23
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. 53 62
12720121 2003
24
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. 53 62
12720146 2003
25
Origins of the malignant clone in typical Waldenstrom's macroglobulinemia. 53 62
12720123 2003
26
Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. 53 62
12351413 2002
27
IL-1beta expression in IgM monoclonal gammopathy and its relationship to multiple myeloma. 53 62
11896542 2002
28
[Association between motoneuron disease and Waldenström macroglobulinemia]. 53 62
11552308 2001
29
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. 53 62
11394505 2001
30
The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. 53 62
11226004 2000
31
Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). 53 62
10350329 1999
32
Waldenström macroglobulinemia-induced bullous dermatosis. 53 62
9762027 1998
33
Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. 53 62
7524765 1994
34
Peripheral neuropathy in IgM monoclonal gammopathy and Wäldenstrom's macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. 53 62
7504399 1994
35
A case-control and family study of Waldenstrom's macroglobulinemia. 53 62
8371587 1993
36
Effect of human biliary immunoglobulins on the nucleation of cholesterol. 53 62
8444895 1993
37
Increased concentrations of total IgM at clinical onset of type 1 (insulin-dependent) diabetes: correlation with IgM binding to cells. The Belgian Diabetes Registry. 53 62
1526011 1992
38
Complete sequence of the genes encoding the VH and VL regions of low- and high-affinity monoclonal IgM and IgA1 rheumatoid factors produced by CD5+ B cells from a rheumatoid arthritis patient. 53 62
1718404 1991
39
Immunoglobulins as nucleating proteins in the gallbladder bile of patients with cholesterol gallstones. 53 62
1856228 1991
40
Transitions in CD45 isoform expression indicate continuous differentiation of a monoclonal CD5+ CD11b+ B lineage in Waldenstrom's macroglobulinemia. 53 62
1708944 1991
41
Chlorpromazine-induced immunopathy: progressive increase in serum IgM. 53 62
2319941 1990
42
Diagnosing Multiple Myeloma and Related Disorders. 62
36270842 2023
43
A fatal case of a CD5-positive lymphoplasmacytic lymphoma with associated AL-type amyloidosis. 62
35596646 2022
44
Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia 62
36373683 2022
45
Bing-Neel síndrome in a patient with Waldenström macroglobulinemia. 62
36123201 2022
46
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States. 62
35876190 2022
47
Bing-Neel Syndrome Successfully Treated with Tirabrutinib. 62
35569989 2022
48
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. 62
36435884 2022
49
Bortezomib-based therapy is effective and well tolerated in frontline and multiply pre-treated Waldenström macroglobulinaemia including BTKi failures: A real-world analysis. 62
36467794 2022
50
Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation. 62
35833301 2022

Variations for Waldenstroem's Macroglobulinemia

Expression for Waldenstroem's Macroglobulinemia

Search GEO for disease gene expression data for Waldenstroem's Macroglobulinemia.

Pathways for Waldenstroem's Macroglobulinemia

Pathways related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.72 MYD88 MIR155 CD40 CCND1 BTK
2
Show member pathways
12.14 ZAP70 PTPRC CD40 BTK
3
Show member pathways
12.05 ZAP70 PTPRC CD40LG CD40
4 12.01 ZAP70 PTPRC PAX5 MYD88 IRF4 CD40LG
5
Show member pathways
11.74 ZAP70 PTPRC MYD88 CD40LG CCND1
6 11.66 PAX5 CCND1 BIRC3
7
Show member pathways
11.64 MIR9-1 MIR206 MIR155
8 11.6 PTPRC MS4A1 IRF4
9
Show member pathways
11.59 CD40LG CD40 BIRC3
10
Show member pathways
11.49 CD40LG CCND1 BIRC3
11 11.46 MYD88 MIR9-1 MIR155
12 11.37 BIRC3 CCND1 MIR155
13 11.35 BTK MYD88 ZAP70
14 11.31 ZAP70 PTPRC CD40LG CD40
15 11.06 ZAP70 CD40LG CD40
16 11 PTPRC CD40LG CD40
17 10.95 PTPRC PAX5 MS4A1 IRF4 CD40LG CD40
18 10.88 CD40LG CD40 BIRC3
19 10.58 ZAP70 PTPRC
20 10.44 MIR206 MAG

GO Terms for Waldenstroem's Macroglobulinemia

Cellular components related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.73 MIR9-1 MIR542 MIR494 MIR206 MIR184 MIR155
2 membrane raft GO:0045121 9.32 ZAP70 PTPRC MAG BTK BIRC3

Biological processes related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 miRNA-mediated gene silencing GO:0035195 10.29 MIR9-1 MIR542 MIR494 MIR206 MIR184 MIR155
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.03 MYD88 CD40LG CD40 BTK
3 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.97 BIRC3 BTK MYD88
4 T cell activation GO:0042110 9.95 ZAP70 PTPRC IRF4
5 positive regulation of B cell proliferation GO:0030890 9.88 BTK CD40 PTPRC
6 positive regulation of tumor necrosis factor production GO:0032760 9.87 PTPRC MYD88 MIR206 BTK
7 positive regulation of isotype switching to IgG isotypes GO:0048304 9.84 PTPRC CD40
8 CD40 signaling pathway GO:0023035 9.83 CD40LG CD40
9 B cell differentiation GO:0030183 9.76 CD40LG MS4A1 PAX5 PTPRC
10 defense response to protozoan GO:0042832 9.73 MYD88 IRF4 CD40
11 positive regulation of alpha-beta T cell proliferation GO:0046641 9.67 ZAP70 PTPRC
12 regulation of immunoglobulin production GO:0002637 9.63 CD40LG CD40
13 B cell proliferation GO:0042100 9.56 PTPRC MS4A1 CD40LG CD40
14 B cell activation GO:0042113 9.23 ZAP70 MS4A1 CD40 BTK

Molecular functions related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 8.92 MIR9-1 MIR494 MIR206 MIR155

Sources for Waldenstroem's Macroglobulinemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....